We describe, to our knowledge, the first published case of a Ph+ AML patient with a BCR-ABL1 breakpoint at e1a3 who subsequently developed an ABL1 T315I mutation after treatment with dasatinib monotherapy. This evidence concerns the gene BCR and acute myeloid leukemia.